A subsidiary of Johnson & Johnson will pay $10 million to settle allegations under the False Claims Act that it promoted a drug-delivery device for unapproved use on children with lymphoma, the Justice Department said.
The case involved a drug and medical device developed by the subsidiary, Therakos Inc., to treat cutaneous T-cell lymphoma, in which cancerous T-cells migrate to the surface of the skin, causing lesions.
The Gores Group, which acquired Therakos from Johnson & Johnson in 2012, will also pay $1.5 million as part of the settlement.
The drug/device system, known as an extracorporeal photopheresis system, involves ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.